Pharmacological Management of insomnia Associated with Parkinson’s Disease
Introduction Parkinson’s disease (PD) is a progressive neurological disorder that associates multiple psychiatric symptoms and disorders, like depression, neurocognitive impairment, sleeping disorders, etc. Insomnia is frequently detected in this population, with a prevalence of over 50% according...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822020983/type/journal_article |
| _version_ | 1797616273947885568 |
|---|---|
| author | O. Vasiliu |
| author_facet | O. Vasiliu |
| author_sort | O. Vasiliu |
| collection | DOAJ |
| description |
Introduction
Parkinson’s disease (PD) is a progressive neurological disorder that associates multiple psychiatric symptoms and disorders, like depression, neurocognitive impairment, sleeping disorders, etc. Insomnia is frequently detected in this population, with a prevalence of over 50% according to several studies.
Objectives
To present a case series dedicated to the treatment of insomnia in patients diagnosed with PD, who did not meet diagnostic criteria for any other psychiatric disorder.
Methods
A number of three patients (2 male, one female, mean age 65.2 years) diagnosed with PD, were evaluated for insomnia. They were all initiated on quetiapine XR 50 mg QD, and up-titrated according to the individual response. All these patients were undergoing treatment for their neurological disease, which remained stable for the next 3 months. A structured clinical evaluation was performed monthly, and safety measurements were also performed. All patients self-evaluated their insomnia severity on a 10-point visual analogic scale (VAS).
Results
After 3 months, patients reported a favorable evolution of their insomnia- VAS score improved significantly to baseline (from 7.3 to 3.3), without significant adverse events (metabolic parameters and QTc values did not change significantly during the treatment period). Daytime sleepiness was not reported as being significant by any of these patients. The mean dose of quetiapine XR used was 75 mg QD (50-150 mg QD), and the mean duration of the needed treatment for insomnia was 8.3 weeks (4-11 weeks).
Conclusions
Quetiapine XR could be useful in patients with PD-related insomnia, and the mean dose is usually below 100 mg QD.
Disclosure
No significant relationships.
|
| first_indexed | 2024-03-11T07:37:43Z |
| format | Article |
| id | doaj.art-1d483f21da69433c9ff734841cbc8589 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:37:43Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-1d483f21da69433c9ff734841cbc85892023-11-17T05:09:03ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S811S81110.1192/j.eurpsy.2022.2098Pharmacological Management of insomnia Associated with Parkinson’s DiseaseO. Vasiliu0Dr. Carol Davila University Emergency Central Military Hospital, Psychiatry, Bucharest, Romania Introduction Parkinson’s disease (PD) is a progressive neurological disorder that associates multiple psychiatric symptoms and disorders, like depression, neurocognitive impairment, sleeping disorders, etc. Insomnia is frequently detected in this population, with a prevalence of over 50% according to several studies. Objectives To present a case series dedicated to the treatment of insomnia in patients diagnosed with PD, who did not meet diagnostic criteria for any other psychiatric disorder. Methods A number of three patients (2 male, one female, mean age 65.2 years) diagnosed with PD, were evaluated for insomnia. They were all initiated on quetiapine XR 50 mg QD, and up-titrated according to the individual response. All these patients were undergoing treatment for their neurological disease, which remained stable for the next 3 months. A structured clinical evaluation was performed monthly, and safety measurements were also performed. All patients self-evaluated their insomnia severity on a 10-point visual analogic scale (VAS). Results After 3 months, patients reported a favorable evolution of their insomnia- VAS score improved significantly to baseline (from 7.3 to 3.3), without significant adverse events (metabolic parameters and QTc values did not change significantly during the treatment period). Daytime sleepiness was not reported as being significant by any of these patients. The mean dose of quetiapine XR used was 75 mg QD (50-150 mg QD), and the mean duration of the needed treatment for insomnia was 8.3 weeks (4-11 weeks). Conclusions Quetiapine XR could be useful in patients with PD-related insomnia, and the mean dose is usually below 100 mg QD. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933822020983/type/journal_articleParkinson diseaseatypical antipsychoticsInsomnia |
| spellingShingle | O. Vasiliu Pharmacological Management of insomnia Associated with Parkinson’s Disease European Psychiatry Parkinson disease atypical antipsychotics Insomnia |
| title | Pharmacological Management of insomnia Associated with Parkinson’s Disease |
| title_full | Pharmacological Management of insomnia Associated with Parkinson’s Disease |
| title_fullStr | Pharmacological Management of insomnia Associated with Parkinson’s Disease |
| title_full_unstemmed | Pharmacological Management of insomnia Associated with Parkinson’s Disease |
| title_short | Pharmacological Management of insomnia Associated with Parkinson’s Disease |
| title_sort | pharmacological management of insomnia associated with parkinson s disease |
| topic | Parkinson disease atypical antipsychotics Insomnia |
| url | https://www.cambridge.org/core/product/identifier/S0924933822020983/type/journal_article |
| work_keys_str_mv | AT ovasiliu pharmacologicalmanagementofinsomniaassociatedwithparkinsonsdisease |